Arbutus和Vaccitech在2a期临床试验中联合慢性乙型肝炎病毒治疗方法向首例患者进行给药
04. Juni 2022 09:43 ET
|
Vaccitech (UK) Limited
宾夕法尼亚州沃明斯特和英国牛津, June 04, 2022 (GLOBE NEWSWIRE) -- 致力于利用广泛的病毒学专业知识开发靶向特定病毒性疾病新型疗法的临床阶段生物制药公司Arbutus Biopharma Corporation（纳斯达克股票代码：ABUS）以及从事新型免疫疗法和疫苗发现及开发的临床阶段生物制药公司Vaccitech...
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
20. Mai 2022 11:30 ET
|
Vaccitech plc
OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments
11. Mai 2022 16:15 ET
|
Vaccitech plc
OXFORD, United Kingdom, May 11, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of...
Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®
06. April 2022 16:15 ET
|
Vaccitech plc
OXFORD, United Kingdom, April 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments
25. März 2022 07:15 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, March 25, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of...
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
07. März 2022 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
18. Januar 2022 03:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient...
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape
13. Januar 2022 16:34 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
13. Dezember 2021 16:05 ET
|
Vaccitech (UK) Limited
Complementary technology platforms, expertise and capabilities provide unique synergistic opportunities.Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvaxTM...
Vaccitech在慢性HBV的1b/2a期临床研究中报告了极具前景的中期疗效分析
07. Dezember 2021 10:30 ET
|
Vaccitech (UK) Limited
在慢性乙型肝炎（CHB）患者中，27名完成了3个月HBV002研究患者的中期数据表明，表面抗原（HBsAg）水平出现了显著变化，特别是在接受具有异源加强型（VTP-300）低剂量纳武单抗的人群中。 HBV002研究招募了4个组来探索初免-加强载体组合，其中包括MVA-HBV（初免）+ MVA-HBV（加强）、ChAdOx1-HBV（初免）+...